Celgene Corp (CELG) 97.90 $CELG
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 19.25 (-0.78), CMG: 403.74 (-5.15), AMGN: 148.80 (-3.47), GOOGL: 700.88 (-13.99), GOOG: 689.19 (-12.68), CELGZ: 1.36 (-0.09), CELG: 97.97 (-2.69)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.99 (-0.04), ANIP: 55.05 (-1.22), RTRX: 17.91 (-0.58), CELG: 97.97 (-2.69)
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
BusinessWire - Wed Jun 22, 6:30AM CDT
Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
CELG: 97.97 (-2.69)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 2.17%
Comtex SmarTrend(R) - Tue Jun 21, 11:55AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $96.55 to a high of $99.80. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $98.22 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 97.97 (-2.69)
Watch for Shares of Celgene (CELG) to Approach Resistance at $101.34
Comtex SmarTrend(R) - Mon Jun 20, 8:47AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $99.13 today and has reached the first level of resistance at $100.04. Should the shares continue to rise, the resistance pivots of $101.34 and $103.55 will be of interest.
CELG: 97.97 (-2.69)
Company News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Companies in the News are: BOBE,TWTR,PN,EBIX,CELG
PN: 8.51 (-0.09), BOBE: 38.60 (-1.09), EBIX: 46.66 (-1.95), TWTR: 16.73 (-0.31), CELG: 97.97 (-2.69)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 97.97 (-2.69), CELGZ: 1.36 (-0.09)
SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.63% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 97.97 (-2.69)
Watch for Celgene to Potentially Rebound After Falling 2.63% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 97.96 (-2.70)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.10 (-0.94), CELGZ: 1.36 (-0.09), CELG: 97.96 (-2.70)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 234.26 (-4.36), SRPT: 17.88 (unch), ALXN: 116.93 (-6.64), AMGN: 148.80 (-3.47), ABBV: 60.40 (-0.91), REGN: 347.77 (-9.37), CELG: 97.96 (-2.70)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Next Support Level for Celgene (CELG) is $105.58
Comtex SmarTrend(R) - Tue Jun 07, 9:11AM CDT
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $107.56 today and has reached the first level of support at $106.61. Investors may be interested in a cross of the next downside pivot targets of $105.58 and $103.60.
CELG: 97.96 (-2.70)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 34.35 (-0.24), BMY: 71.52 (-1.12), CORT: 5.23 (-0.24), CELG: 97.96 (-2.70)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Downgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Thu Jun 02, 3:27AM CDT
Celgene (NASDAQ:CELG) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $106.02 on volume of 2.9 million shares, below average daily volume of 4.7 million. There is potential upside of 36.3% for shares of Celgene based on a current price of $106.02 and an average consensus analyst price target of $144.47. Celgene shares should encounter resistance at the 200-day moving average (MA) of $112.65 and support at the 50-day MA of $103.40.
CELG: 97.96 (-2.70)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.92 (-0.40), VRTX: 84.90 (-3.30), VZ: 54.99 (+0.32), NVDA: 47.16 (-1.33), CELGZ: 1.36 (-0.09), CELG: 97.96 (-2.70)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.38% Rise
Comtex SmarTrend(R) - Tue May 24, 2:15PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $101.32 to a high of $103.85. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $102.41 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 97.96 (-2.70)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 19.25 (-0.78), CMG: 403.74 (-5.15), AMGN: 148.80 (-3.47), GOOGL: 700.88 (-13.99), GOOG: 689.19 (-12.68), CELGZ: 1.36 (-0.09), CELG: 97.97 (-2.69)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.99 (-0.04), ANIP: 55.05 (-1.22), RTRX: 17.91 (-0.58), CELG: 97.97 (-2.69)
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
BusinessWire - Wed Jun 22, 6:30AM CDT
Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
CELG: 97.97 (-2.69)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 2.17%
Comtex SmarTrend(R) - Tue Jun 21, 11:55AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $96.55 to a high of $99.80. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $98.22 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 97.97 (-2.69)
Watch for Shares of Celgene (CELG) to Approach Resistance at $101.34
Comtex SmarTrend(R) - Mon Jun 20, 8:47AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $99.13 today and has reached the first level of resistance at $100.04. Should the shares continue to rise, the resistance pivots of $101.34 and $103.55 will be of interest.
CELG: 97.97 (-2.69)
Company News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Companies in the News are: BOBE,TWTR,PN,EBIX,CELG
PN: 8.51 (-0.09), BOBE: 38.60 (-1.09), EBIX: 46.66 (-1.95), TWTR: 16.73 (-0.31), CELG: 97.97 (-2.69)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 97.97 (-2.69), CELGZ: 1.36 (-0.09)
SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.63% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 97.97 (-2.69)
Watch for Celgene to Potentially Rebound After Falling 2.63% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 97.96 (-2.70)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.10 (-0.94), CELGZ: 1.36 (-0.09), CELG: 97.96 (-2.70)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 234.26 (-4.36), SRPT: 17.88 (unch), ALXN: 116.93 (-6.64), AMGN: 148.80 (-3.47), ABBV: 60.40 (-0.91), REGN: 347.77 (-9.37), CELG: 97.96 (-2.70)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Next Support Level for Celgene (CELG) is $105.58
Comtex SmarTrend(R) - Tue Jun 07, 9:11AM CDT
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $107.56 today and has reached the first level of support at $106.61. Investors may be interested in a cross of the next downside pivot targets of $105.58 and $103.60.
CELG: 97.96 (-2.70)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 34.35 (-0.24), BMY: 71.52 (-1.12), CORT: 5.23 (-0.24), CELG: 97.96 (-2.70)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance. CELG: 97.96 (-2.70), CELGZ: 1.36 (-0.09)
Downgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Thu Jun 02, 3:27AM CDT
Celgene (NASDAQ:CELG) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $106.02 on volume of 2.9 million shares, below average daily volume of 4.7 million. There is potential upside of 36.3% for shares of Celgene based on a current price of $106.02 and an average consensus analyst price target of $144.47. Celgene shares should encounter resistance at the 200-day moving average (MA) of $112.65 and support at the 50-day MA of $103.40.
CELG: 97.96 (-2.70)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.92 (-0.40), VRTX: 84.90 (-3.30), VZ: 54.99 (+0.32), NVDA: 47.16 (-1.33), CELGZ: 1.36 (-0.09), CELG: 97.96 (-2.70)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.38% Rise
Comtex SmarTrend(R) - Tue May 24, 2:15PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $101.32 to a high of $103.85. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $102.41 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 97.96 (-2.70)
